FDMT – 4d molecular therapeutics, inc. (US:NASDAQ)
Stock Stats
News
4D Molecular Therapeutics (FDMT) was upgraded by Wall Street Zen from
4D Molecular Therapeutics (FDMT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $36.00 price target on the stock.
4D Molecular Therapeutics (FDMT) had its price target raised by Royal Bank Of Canada from $32.00 to $35.00. They now have an "outperform" rating on the stock.
4D Molecular Therapeutics (FDMT) had its "buy" rating reaffirmed by Chardan Capital. They now have a $26.00 price target on the stock.
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
Form 4 4D Molecular Therapeutic For: Mar 20 Filed by: Gupta Ashoo
Form S-8 4D Molecular Therapeutic
Form 10-K 4D Molecular Therapeutic For: Dec 31
Form 8-K 4D Molecular Therapeutic For: Mar 18
Form SCHEDULE 13G/A 4D Molecular Therapeutic Filed by: Novo Holdings A/S
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.